Centre for Therapeutic Target Validation welcomes Biogen, expanding efforts to accelerate drug discovery research
Protein screens developed at EMBL Hamburg now commercially available
Former Head of EMBL Grenoble passed away on 21 January 2016 at the age of 89
"We’re open! We’re open to working with everybody, we’re open to new things."
Hamburg collaborators analyse protein crystals inside the cells that made them.
Further insights into how viral enzymes degrade the cell walls of Clostridia bacteria.
Scientist and showman: PhD student Vasily Sysoev shares his passion for outreach.
New method is first to enable parallel profiling of the transcriptome and epigenome of a single cell.
From initial development to a start-up company: Selective Plane Illumination Microscopy (SPIM) at EMBL.
With 28 conferences and 57 courses, 2016 will be EMBL’s most eventful year to date.
New microscope can record the first days of a mouse embryo’s life
Making it easier to visualise, understand and predict how proteins combine to drive biological processes.
Two PhD students sink their teeth into the science and speculations of Jurassic Park.
Identifying evidence-based relationships between drug targets and diseases.